Press release
Pulmonary Drugs Market: Advent of Middle-income Classes to Catapult Demand in Asia Pacific
The global Pulmonary Drugs Market is highly competitive in nature with a few products dominating the overall market, states a new research report by Transparency Market Research. The leading players in the market are expected to lose their share to certain extent as patents of several drugs are going to expire in the next few years. In order to maintain its position and market share, the key players are focusing on building their drug pipelines and enhancing developing result-oriented and effective medicines in order to meet the unmet demand of the patients worldwide. Some of the key players operating in the pulmonary drugs market across the globe are Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Astra Zeneca, Teva Pharmaceutical Industries Ltd., and Merck & Co., Inc.As per the market research study published by Transparency Market Research, in 2015, the global market for pulmonary drugs market was worth US$ 48,039.7 mn and is predicted to reach a value of US$ 28,082.1 mn by the end of 2024. The market is anticipated to register a -6.30% CAGR between 2016 and 2024.
Request to View Sample of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16751
On the basis of geography, the global pulmonary drugs market has been classified into the Middle East and Africa, Latin America, North America, Europe, and Asia Pacific. As per the report, in 2015, the North America market accounted for a share of 41% of the global market and is expected to remain in the leading position throughout the forecast period. North America is expected to be followed by Europe in the next few years. The development of the advanced healthcare infrastructure and the rising awareness among people regarding the availability of pulmonary diseases. On the flip side, a significant rise in the income of middle-class people and their willingness to spend on advanced healthcare is projected to accelerate the growth of the pulmonary drugs market in the coming few years.
On the basis of drug classes, the global pulmonary drugs market has been categorized into anticholinergics, combination drugs, short acting beta2-agonists, antihistamines, vasodilators, long-acting beta2-agonists, inhaled corticosteroids, and others. The combination drugs segment held a large share of the global market in the last few years and is projected to remain in the leading position throughout the forecast period. The high growth of this segment can be attributed to the fact that combination drugs are considered safe in comparison with other drugs. In addition to this, the advent of triple combination drugs is likely to generate promising growth opportunities throughout the forecast period.
Request to View Brochure of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16751
The demand for pulmonary drugs, despite the expected decline is likely to rise with the increasing prevalence of chronic respiratory disorders. A tremendous rise in the number of smokers around the world is also considered as a major factor estimated to accelerate the growth of the pulmonary drugs market in the next few years. In addition to this, the research and development activities and the awareness programs being conducted by government across the globe are estimated to encourage the growth of the market in the coming years.
View Report -
https://www.transparencymarketresearch.com/pulmonary-drugs-market.html
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Drugs Market: Advent of Middle-income Classes to Catapult Demand in Asia Pacific here
News-ID: 1167438 • Views: …
More Releases from Transparency Market Research
Global Opioid Induced Constipation Treatment Market Set to Reach USD 5.2 Billion …
The global opioid induced constipation (OIC) treatment market is witnessing steady and sustained growth as healthcare systems worldwide place increasing emphasis on comprehensive pain management and supportive care. Valued at US$ 2.9 billion in 2025, the market is projected to reach US$ 5.2 billion by 2036, expanding at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2036. Growth is primarily fueled by the rising prevalence of chronic…
Pneumatic Flux Chipper Market Expanding at 7.4% CAGR Through 2036 - By Product T …
The global Pneumatic Flux Chipper Market is set to witness sustained and resilient growth over the next decade, underpinned by expanding heavy manufacturing activities, rising welding and fabrication demand, and continuous investments in industrial infrastructure across emerging and developed economies. According to the latest industry analysis, the market was valued at US$ 760.5 Mn in 2025 and is projected to reach US$ 1,680.8 Mn by 2036, expanding at a compound…
AI in Automotive Market Outlook 2036: Global Industry to Surge from US$ 19.8 Bil …
The AI in automotive market is entering a phase of exponential expansion, supported by rapid digitization of vehicles, growing safety mandates, and consumer demand for intelligent mobility. The global market was valued at US$ 19.8 Bn in 2025 and is projected to reach US$ 244.4 Bn by 2036, registering a remarkable CAGR of 27% from 2026 to 2036.
This growth trajectory reflects the transition of automobiles from mechanically driven products to…
Hypodermic Needles Market to Reach US$ 7.9 Billion by 2036 on Rising Injectable …
The global hypodermic needles market was valued at approximately US$ 4.2 billion in 2025 and is projected to reach around US$ 7.9 billion by 2036, expanding at a CAGR of nearly 5.8% from 2026 to 2036, driven by the rising prevalence of diabetes, cancer, and chronic diseases, growing demand for injectable drugs and biologics, and the expansion of global vaccination and immunization programs; increasing adoption of safety-engineered and disposable needles,…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
